DEA Okays Bulk Pot Production for Researchers: Objections Invited
Published Date: 1/23/2026
Notice
Summary
Maridose LLC wants to become a big-time maker of marijuana and related substances to help researchers study them. People already registered or interested can share their thoughts or ask for a hearing by March 24, 2026. This move could speed up research but doesn’t change any other drug rules or costs right now.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
New Supplier for DEA Research Cannabis
On January 1, 2026, Maridose LLC applied to be a DEA-registered bulk manufacturer of marihuana (code 7360), marihuana extract (code 7350), and tetrahydrocannabinols (code 7370), all Schedule I substances. If registered, the company would be allowed to manufacture these substances in bulk to supply Drug Enforcement Administration–registered researchers for their approval studies; no other activities for these drug codes would be authorized. Comments or requests for a hearing must be submitted by March 24, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17429, Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
The Drug Enforcement Administration (DEA) is issuing this temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these three 7-hydroxymitragynine-related substances.
2026-17385, Importer of Controlled Substances Application: Experic LLC
Experic LLC wants to become an official importer of some controlled substances, including certain drugs like tetrahydrocannabinols and nabilone. People and companies already registered can share their thoughts or ask for a hearing by September 25, 2026. This move could impact businesses dealing with these substances, so keep an eye on the deadline to have your say!
2026-17275, Catina Allen, N.P.; Decision and Order
Catina Allen, a nurse practitioner from Indiana, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired on June 30, 2026. This means she can’t prescribe or manage controlled drugs anymore, affecting her medical practice and patients.
2026-17285, Importer of Controlled Substances Application: Prof Compounding CTS of Ameri
Prof Compounding CTS of Ameri has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Previous / Next Documents
Previous: 2026-01297, Application for Authorization To Export Electric Energy; Electric Power Markets USA, LLC
Electric Power Markets USA, LLC wants permission to send electricity from the U.S. to Mexico for the next five years. This affects energy buyers and sellers in Texas and could boost cross-border power trade without hurting U.S. electricity supplies. If you have thoughts or concerns, you’ve got until February 23, 2026, to speak up!
Next: 2026-01305, Bulk Manufacturer of Controlled Substances Application: Organic Consultants LLC DBA Cascade Chemistry
Organic Consultants LLC, also known as Cascade Chemistry, wants to become a big-time maker of certain controlled drugs like codeine and oxycodone. They plan to produce small amounts mainly for testing and research. If you have thoughts or objections, you’ve got until March 24, 2026, to speak up online—no cost involved!